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ABSTRACT  
The aim of the present work is to formulate, optimize and evaluate hydrodynamically balanced antidiabetic system incorporated with 
sitagliptin and phytochemical constituents of Triphala extract for the treatment of constipation associated with diabetes.  The Triphala churna 
of two different ratios, 1:1:1 (TC1) and 1:2:4 (TC2) were subjected to hot percolation using Soxhlet apparatus using methanol as solvent. The 
floating matrix tablets of Sitagliptin with methanolic Triphala extract was prepared by wet granulation technique using HPMC K4M as polymer, 
starch/honey as binder and sodium bicarbonate & citric acid as effervescent agents by 24 factorial design.  The compatibility studies showed 
that there is no chemical interaction between the drug, polymer and the excipients used in the tablets.  The independent variables are drug & 
Triphala extract ratio (X1), Triphala proportion (X2), binder used for granulation (X3), and amount of effervescent excipients used (X4).  The 
dependent variables are hardness (Y1), buoyancy lag time (Y2), total floating time (Y3), in-vitro drug release (Y4), and T50% (Y5).  The 
prepared floating tablets were subjected to all post compression parameters such as hardness, friability, swelling capacity, buoyancy, total 
floating time, drug content & in-vitro drug release and were found to be within normal limits.  Based on drug content, buoyancy lag time and in-
vitro drug release the formulations F14 and F16 were selected for in-vivo study of the formulation.   
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INTRODUCTION 
Floating systems or hydrodynamically controlled systems 
are low-density systems that have sufficient buoyancy to 
float over the gastric contents and remain buoyant in the 
stomach without affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating on the 
gastric contents, the drug is released slowly at the desired 
rate from the system. Floating drug delivery systems have 
emerged as an efficient means of enhancing the 
bioavailability and controlled delivery of many drugs. The 
increasing sophistication of delivery technology will ensure 
the development of increase number of gastroretentive drug 
delivery to optimize the delivery of molecules. [1] 
Sitagliptin is a dipeptidyl-peptidase inhibitor that has been 
approved for the therapy of type 2 diabetes. Sitagliptin is 
effective in lowering HbA1c, and fasting as well as 
postprandial glucose in monotherapy and in combination 
with other oral antidiabetic agents. [2]  Treatment with 
sitagliptin was not associated with an increased risk of 
major adverse cardiovascular events, malignancy, or 
pancreatitis but was associated with constipation as adverse 
effect in patients. [3] 
Triphala is a traditional ayurvedic herbal formulation 
composed of three medicinal plants, Terminalia chebula, 
Terminalia bellirica, and Emblica officinalis which means the 
combination of three fruits. Triphala is the most popular 
ayurvedic herbal formula of India, because it combines the 
properties of both a purgative and lubricating bulk laxative. 
[4] Functional constipation can be managed by using a non-
habit-forming herbal laxative formulation that included 
Triphala as one of the ingredient and was found to be 
effective and safe. [5]   
In the present work, an attempt is made to fabricate a 
hydrodynamically controlled floating tablets of sitagliptin 
with Triphala extract along with other excipients such as 
polymer, effervescent ingredients etc.  16 formulations were 
developed with an objective of achieving more than 10 hrs 
floating and drug release by using 24 factorial design. 
MATERIALS AND METHOD  
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Chemicals  
Sitagliptin was obtained as a gift sample from Richer 
Pharmaceuticals, Hyderabad, HPMC K4M was obtained from 
Yarrow Chem Products, Mumbai, sodium bicarbonate & 
citric acid were obtained from Loba Chemie Pvt. Ltd. 
Mumbai, starch, magnesium stearate, talc were obtained 
from SD Fine Chemicals and honey was obtained from Khadi, 
Salem.  All the other chemicals used were of analytical grade. 
Collection and identification of Triphala fruits 
The fruit specimens of Terminalia chebula, Terminalia 
bellirica and Emblica officinalis were collected in and around 
Rajahmundry, Andhra Pradesh.  The fruit specimens were 
identified and authenticated by Dr. J. Suneetha M.Sc., M.Phil., 
PhD, Professor and Head, Department of Botany, 
Government Art College, Rajahmundry, Andhra Pradesh.  
Specimen No: GAC/RJ/BO/2019/03/34.   A voucher 
specimen was stored in our laboratory. 
Preparation of Triphala churna 
The dried fruits of Triphala is pulverised into fine powder 
using a stainless steel electrical mixer and passed through # 
100 mesh sieves.  Then, the powders of Terminalia bellirica, 
Emblica officinalis, and Terminalia chebula are mixed in ratio 
of 1:1:1 (TC1) and 1:2:4 (TC2) and stored in an airtight 
container for extraction. 
Preparation of aqueous and methanolic extracts of 
Triphala 6, 7 
An accurately weighed powder of formulations TC1 & TC2 
were subjected to hot percolation in a Soxhlet extractor with 
75% of methanol at 80°C to get methanolic extract. The 
Triphala powders (TC1 &TC2) were added in boiling solvent 
in a percolator for 2 h and then the process of hot continous 
percolation was continued.  The resultant extract was 
concentrated using rotary vacuum evaporator.  This 
concentrated extract is evaporated to dryness over a water 
bath and stored in a desiccator.   
PREFORMULATION STUDIES 
Solubility8, 9 
100 mg of Sitagliptin is dissolved in 1 ml of different types of 
solvents such as water, simulated gastric fluid of pH 1.2, pH 
6.8 buffer & pH 7.2 buffer.  Every 10 mg of drug is added 
periodically to check the complete solubility of drug in 1 ml 
of various solvents. 
Compatibility Studies10 
Fourier Transform Infrared Spectrometry (FTIR): 
Compatibility study of drug with the excipient was 
determined by I.R. Spectroscopy (FT-IR) using Perkin Elmer 
spectrum RX1 FT-IR spectrometer model.  The pellets were 
prepared at high compaction pressure by using KBr and the 
ratio of sample to KBr is 1:100.  The pellets thus prepared 
were examined and the spectra of drug with other 
ingredients in the formulations were compared with that of 
the original spectra. 
Preparation of Simulated Gastric Fluid (Without 
Enzyme) 11 
Required amount of sodium chloride was dissolved in 
concentrated hydrochloric acid and is diluted to 1000 ml 
with distilled water to obtain a solution of pH 1.2. 
Formulation of Floating Tablets 
Hydrodynamically balanced floating matrix tablets were 
formulated with Sitagliptin and methanolic Triphala extract 
by wet granulation method using 24 full factorial design.  The 
active ingredient was mixed with Triphala extract, HPMC 
K4M, sodium bicarbonate, citric acid, and magnesium 
stearate using 10% w/v starch paste or 10% v/v honey as 
binder to make a good wet mass of granules.  Talc is used as 
a glidant with granules for free flowing of granules into 
punches. The proportion of Triphala extract used is 1:1:1 
(TC1) and 1:2:4 (TC2) of Terminalia bellirica, Emblica 
officinalis, and Terminalia chebula.  After mixing well, the 
granules were passed through #60 mesh sieve and dried in 
hot air oven at 40°C for 45 minutes for complete drying.  
Finally, the mixture was weighed and compressed on an 8 mm flat face punch machine. 
Statistical Optimization Technique12, 13 
The optimization was designed statistically using 24 full 
factorial design. A 2-level full-factorial design consists of 16 
full-factorial design points as in Table 1. 
  
Table 1: Layout of 24 full factorial design13 
F. Code F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 
X1 -1 -1 -1 -1 -1 -1 -1 -1 +1 +1 +1 +1 +1 +1 +1 +1 
X2 -1 -1 -1 -1 +1 +1 +1 +1 -1 -1 -1 -1 +1 +1 +1 +1 
X3 -1 -1 +1 +1 -1 -1 +1 +1 -1 -1 +1 +1 -1 -1 +1 +1 
X4 -1 +1 -1 +1 -1 +1 -1 +1 -1 +1 -1 +1 -1 +1 -1 +1 
 
 
This design generally involves independent variables X1, X2, 
X3, & X4. The dependent formulation variables selected are 
Y1, Y2, Y3, Y4, and Y5. The levels of independent variables 
and the dependent formulation variables are shown in table 
2 & table 3 respectively.  The results obtained from the 
experiment were statistically analyzed for response 
variables by using Minitab Statistical Software (Version 17). 
The statistical model incorporating interactive and 
polynomial terms was used to evaluate the response. 
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STATISTICAL OPTIMIZATION 
Table 2: Independent Variables 
Code Variables Low level (-1) High Level (+1) 
X1 Sitagliptin: Triphala extract ratio 50 mg: 300 mg 50 mg: 600 mg 
X2 Triphala proportion 1:1:1 (TC1) 1:2:4 (TC2) 
X3 Binder proportion 10% w/v  starch paste 10% v/v honey 
X4 Sodium bicarbonate: Citric acid 100 mg: 30 mg 150 mg: 45 mg 
 
Table 3:  Dependent Variables 
Code Dependent Variables 
Y1 Hardness 
Y2 Buoyancy lag time 
Y3 Total floating time 
Y4 In-vitro drug release at 12 hrs 
Y5 T 50% 
 
Physicochemical evaluation of floating tablet14 
Pre-Compression Parameters:  
Angle of repose 
In order to determine the flow property, the angle of repose 
was determined. It is the maximum angle that can be 
obtained between the free standing surface of the powder 
heap and the horizontal plane.  = tan -1 (h/r) 
Where,   h = height, r = radius,  = Angle of repose 
Bulk density and tapped density 
A quantity of 5 gm of the powder (W) from each formula was 
introduced into a 25 ml measuring cylinder.   After the initial 
volume (Vo) was observed, the cylinder was allowed to fall 
under its own weight onto a hard surface from the height of 
2.5 cm at 2 sec intervals.   The tapping was continued until 
no further change in volume was noted.  The bulk density, 
and tapped density were calculated using the following 
formulas  
Bulk density = W / Vo         and      Tapped density = W / Vf 
Where,     W=   weight of the powder,  
Vo = initial volume, Vf = final tapped volume 
Compressibility index ȋCarr’s indicesȌ 
Compressibility index is an important measure that can be 
obtained from the bulk and tapped densities.  In theory, the 
less compressible a material the more flow able it is. A 
material having values of less than 20 to 30% is defined as 
the free flowing material. The limits are mentioned in the 
table below.    
CI   = 100(VO – Vf)/V 
(ausner’s Ratio 
It indicates the flow properties of the powder and is 
measured by the ratio of tapped density to the bulk density. Hausner’s Ratio = Tapped density/Bulk density  
             = (W / Vf) / (W / Vo)  
where,  
W / Vf  = Tapped density      and     W / Vo = Bulk density.  
Post-Compression Parameters14: 
Tablet Dimensions  
Thickness and diameter were measured using a calibrated 
dial caliper.  Three tablets of each formulation were taken 
randomly and thickness & diameter were measured 
individually. 
 Hardness  
The hardness of the tablets was determined using Monsanto 
Hardness Tester.  Three tablets were randomly picked in 
each formulation and hardness of the tablets was 
determined. 
Friability  
The friability of tablets was determined using Roche 
friabilator. Ten tablets were initially weighed (wo initial) and 
transferred into friabilator. The friabilator was operated to 
run at 25 rpm for 4 minutes or run up to 100 revolutions.  
The tablets were weighed again (w -final).  The percentage 
friability was then calculated by  
Percentage of friability = ቀ     ቁ      
Weight Variation 
Twenty tablets were selected at random and the average 
weight was determined.  Not more than two of the individual 
weights deviate from the average weight by more than the 
percentage deviation shown in table below. 
Table 4: Weight Variation Tolerances for Uncoated 
Tablets 
S. 
No. 
Average weight of 
Tablets (mg) 
Maximum difference 
allowed (%) 
1. 130 or Less 10 
2. 130 to 324 7.5 
3. More than 324 5.0 
 
% Maximum positive deviation = (WH –A/ A) x 100 
% Minimum negative deviation = (A-WL/ A) x 100 
Where, WH  =  Highest weight in mg,      
WL  =  Lowest weight in mg. 
A   = Average weight of tablet in mg 
 
Revathi et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):38-47 
ISSN: 2250-1177                                                                                  [41]                                                                                 CODEN (USA): JDDTAO 
Tablet Density  
Tablet density is an important parameter for floating tablets. 
The tablet will float when its density is less than that of 
gastric fluid (1.004g/cc).  The density decreases due to the 
expansion and upward force of CO2 gas generation. The 
density was determined using following formula.  
            v =  r2h & d = m/v 
Where, v = volume of tablet (cc),  r = radius of tablet (cm), 
h = crown thickness of tablet (mm), m = mass of tablet 
Buoyancy / Total Floating Time15 
The time between introduction of dosage form and its 
buoyancy on the simulated gastric fluid and the time during 
which the dosage form remain buoyant were measured. The 
tablets were placed in a 100 ml beaker containing simulated 
gastric fluid.  The time required for the tablet to rise to the 
surface and float was determined as floating lag time. The 
duration of time the dosage form constantly remained on the 
surface of the medium was determined as the total floating 
time. 
Swelling Study16  
The individual tablets were weighed accurately and kept in 
50 ml of water. Tablets were taken out carefully after 60 min 
blotted with filter paper to remove the water present on the 
surface and weighed accurately.  Percentage swelling was 
calculated by using the following formula.                                                  
Test for Content Uniformity 
The absorbance of both the standard preparation and the 
sample preparation after suitable dilutions were measured 
in a UV-visible spectrophotometer at 267 nm using 0.1 N HCl 
as blank. The same procedure was repeated for three times. 
In-vitro Drug Release Study10 
In-vitro release studies were carried out using USP type II, 
paddle dissolution test apparatus. 900ml of simulated 
gastric fluid was taken in dissolution vessel and the 
temperature of the medium was maintained at 37°C  0.5°C.  
The speed of rotation of paddle was 50 rpm. 1 ml of sample 
was withdrawn at predetermined time intervals and same 
volume of fresh medium was replaced.  The samples were 
analyzed for drug content against simulated gastric fluid as a 
blank at  max 267 nm using UV Spectrophotometer. 
RESULTS AND DISCUSSION 
The solubility studies of Sitagliptin showed that the highest 
amount of solubility is in distilled water, then in simulated 
gastric fluid at pH 1.2.  The alkaline solutions show less 
solubility of Sitagliptin than in simulated gastric fluid at pH 
1.2. 
The FT-IR Spectrum of pure Sitagliptin was compared with 
the FT-IR spectrum of physical mixture of tablet (Figure 3). 
There was no appearance or disappearance of any 
characteristics peaks.  This shows that there is no chemical 
interaction between the drug and the excipients used in the 
tablet. The presence of peaks at the expected range confirms 
that the materials taken for the study are genuine. 
Fig 1:  Solubility of Sitagliptin 
 
 
Fig 2: Standard curve of Sitagliptin 
 
 
Fig 3: FT-IR spectra of Sitagliptin + Excipients 
 
The mixture of all formulations was evaluated for pre-
compression parameters before compression into tablets for angle of repose, bulk density, tapped density, Hausner’s 
ratio, compressibility index and was found to be within 
normal limits and the powder has cohesive properties.
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Fig 4: Buoyancy after 2 min       Fig 5: Buoyancy after 2 hours 
      
 
Fig 6:  Buoyancy of formulations F1 – F16 
 
 
The tablets of all formulation were subjected to various 
evaluation parameters such as average weight, thickness, 
diameter, hardness, friability, tablet density, in-vitro 
buoyancy lag time, total floating time, swelling index, drug 
content and in-vitro dissolution study.  The results of all 
these tests were found to be satisfactory.  The buoyancy and 
total floating time of the formulations were from 27 sec to 
139 sec and 4.3 to 9.3 hr respectively.  As the effervescence 
excipient concentration has increased the total floating time 
of the formulations have also increased. The buoyancy has 
increased because the total weight of the tablet had 
increased which made the effervescence excipients delay to 
diffuse out of the tablet.  
All the formulations using 10% v/v honey as the binding 
agent showed extended time for drug release when 
compared to that of the 10% starch as the binder.  This 
shows the more binding capacity of honey than the starch. 
All the formulations in which higher amount of 
effervescence excipients are used showed more percentage 
of drug release since the effervescence allowed more 
amount of solvent to diffuse through the formulation 
surface.  The formulations using TC2 took more time to 
release the drug when compared to that of TC1 may be 
because of more binding capacity of phytochemical 
constituent to the binder.  The formulations using higher 
amount of extract took extended time for complete drug 
release up to 11 hours.  This is obviously because of increase 
in tablet weight and lesser diffusivity of solvent into the 
formulation.  Overall, the highest amount of drug release 
was found as 98.85 % and 98.97% in 10 and 11 hours of the 
formulations F14 and F16 respectively. 
All the formulations exhibited zero-order drug release 
showing the rate of drug release is independent of the 
concentration of the drug present in the formulation.  
Formulations F1 –F8 were best fit into Higuichi’s and 
formulations F9 – F16 were best fit into Korsmeyer-Peppa’s 
indicating that the diffusion is the dominant mechanism of 
drug release in these formulations.  The mechanism of drug 
release was found to be non-Fickian or anomalous drug 
release.
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Table 5: Kinetic values of formulations F1-F16  
F.code 
Zero –order First -order Higuichi’s Korsemeyer-Peppa’s 
R2 R2 R2 R2 
F1 0.949 0.909 0.989 0.988 
F2 0.898 0.846 0.988 0.975 
F3 0.938 0.928 0.991 0.981 
F4 0.927 0.853 0.996 0.992 
F5 0.958 0.856 0.981 0.980 
F6 0.954 0.857 0.987 0.987 
F7 0.938 0.843 0.980 0.973 
F8 0.931 0.764 0.981 0.974 
F9 0.986 0.848 0.969 0.991 
F10 0.985 0.812 0.973 0.994 
F11 0.991 0.836 0.958 0.989 
F12 0.989 0.773 0.964 0.992 
F13 0.994 0.809 0.942 0.986 
F14 0.993 0.742 0.943 0.983 
F15 0.996 0.853 0.937 0.988 
F16 0.997 0.771 0.942 0.995 
 
Fig 7:  In-vitro dissolution of F1-F8 
 
Fig 8:  In-vitro dissolution of F9 – F16 
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Fig 9: Surface plot of Y1 vs X1 & X3    Fig 10: Surface plot of Y1 vs X2 & X3 
 
 
Fig 11:  Surface plot of Y2 vs X1 & X4    Fig 12:  Surface plot of Y2 vs X2 & X4 
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Fig 13:  Surface plot of Y3 vs X1 & X4  Fig 14:  Surface plot of Y3 vs X2 & X4 
 
 
Fig 15:  Surface plot of Y4 vs X1 & X3  Fig 16:  Surface plot of Y4 vs X1 & X4 
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Fig 17:  Surface plot of Y5 vs X1 & X4 Fig 18:  Surface plot of Y5 vs X2 & X4 
 
 
Table 6:  Regression equations of dependent factors 
S. No REGRESSION EQUATIONS R2 
1 Y1 = 8.537 - 0.000900 X1 - 0.00423 X2 + 0.3950 X3  + 0.002038 X4 89.25 
2 Y2 = -252.1 + 0.22083 X1  + 2.000 X2  + 10.50 X3  - 0.1231 X4 99.39 
3 Y3 = -17.90 + 0.005625 X1 + 0.1740 X2  + 0.112 X3 + 0.01135 X4 95.53 
4 Y4 = 287.1 - 0.11052 X1 - 1.447 X2 - 7.43 X3 + 0.0408 X4 96.89 
5 Y5 = -9.548 + 0.007612 X1 + 0.07817 X2 + 0.4463 X3 - 0.002327 X4 99.58 
 
Results of ANOVA  
From the results of ANOVA it was observed that the 
independent factors X1 (Drug: TE ratio) and X3 (binder) 
influences the dependent factor Y1 (hardness).  Honey 
showed more binding capacity than starch.  Increase in 
concentration of TE in formulation slightly influenced by 
little decrease in the hardness of the tablet in few 
formulations only.  
Buoyancy (Y2) is influenced by drug: TE ratio (X1), Triphala 
ratio (1:2:4) and amount of effervescent (X4).  Increase in 
concentration of Triphala extract has increased the time of 
buoyancy of the formulations.  Increase in concentration of 
effervescent excipients decrease the buoyancy lag time of 
the formulations.  TC2 extract has increase the time of 
buoyancy than TC1. 
Total floating time (Y3) was influenced by X1, X2, & X4.  
Increase in concentration of Triphala extract (X1) increase 
the total floating time.  The ratio of Triphala (X2) has slight 
effect on total floating time by increasing the TFT when TC2 
is used.  Effervescent excipients (X4) have high influence on 
total floating time by increasing it.  
Percentage of drug release at 4th hour (Y4) was affected by 
binder (X3) and slight effect by amount of effervescent (X4).  
Honey increased the binding capacity of granules, there by 
decrease the percentage of drug release by time.  Increase in 
concentration of effervescent increased the percentage of 
drug release very lightly, may be due to the diffusivity of CO2 
out of formulations. 
T50% of drug (Y5) was affected by Triphala extract 
concentration (X1).  The increase in concentration of 
Triphala extract increased the T50%.  This may be due to 
dispersion of drug in Triphala extract.  Amount of 
effervescent (X4) has no effect on T50%.  Triphala ratio (X2) 
has slight effect on T50%.  It showed a slight increase in time 
of release for T50% when TC2 is used. 
CONCLUSION 
The FT-IR reports showed that the Triphala extract is 
compatible Sitagliptin and all other excipients used for 
formulation.  The hydrodynamically balanced tablets were 
then prepared by wet granulation method and were 
optimized using 24 full factorial design.  All the pre-
compression and post compression parameters were 
evaluated and found to be within acceptable limits.  All the 
formulations exhibited zero-order drug release and non-
fickian or anomalous diffusion is dominant mechanism in 
drug release since it best fit in Korsmeyer-Peppa’s.    
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